Phase 3 Cardiogenic Shock Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Cardiogenic Shock
Pr Bruno LEVY610 enrolled28 locationsNCT04020263
Recruiting
Phase 3
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Cardiogenic Shock
Central Hospital, Nancy, France164 enrolled8 locationsNCT05879276
Recruiting
Phase 3
Paramedic Randomized Trial of Noradrenaline Versus Adrenaline in the Initial Management of Patients with Cardiogenic Shock: The PANDA Trial
Cardiogenic Shock
Ambulance Victoria1,155 enrolled1 locationACTRN12621000805875